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L E T T E R  T O  T H E  E D I T O R
The interaction of factor V and tissue factor pathway inhibitor 
in a myeloma patient with acquired factor V deficiency
Factor V (FV) is an essential coagulation factor, which participates in 
both pro- and anticoagulant pathways.1 Its deficiency is associated 
with a wide spectrum of bleeding symptoms. Congenital FV defi-
ciency is caused by mutations in the F5 gene, in contrast to acquired 
FV deficiency, which is mostly caused by a neutralizing antibody. 
The latter can be induced by auto- immune disorders, malignancy, or 
treatment with antibiotics or topical bovine thrombin.2 The presence 
of such inhibitors should emerge in mixing studies and in a Bethesda 
assay. Cases of acquired FV deficiency without evidence of an in-
hibitor are rarely described. Here, we report such a case. The patient 
was a 45- year- old woman with multiple myeloma who had reached 
complete remission following autologous stem cell transplantation 
after induction therapy with Velcade® (bortezomib), cyclophospha-
mide and dexamethasone. She was also treated with radiotherapy 
for bone disease. Five months later, the patient relapsed with an ag-
gressive form of multiple myeloma with deletion of p53. Treatment 
with Kyprolis® (carfilzomib), Revlimid® (lenalidomide) and dexa-
methasone was started with good response during the first months. 
However, after 4 months she developed hypercalcemia, thrombocy-
topenia and episodes of high fever due to progression of the disease 
and she was admitted to our haematology department. During her 
stay, she developed supraventricular tachycardia and she was trans-
ferred to the intensive care unit (ICU). At that point, the first prolon-
gation of the activated partial thromboplastin time (aPTT, seconds) 
was noticed. The next day, the prothrombin time (PT, seconds) also 
started to increase. PT and aPTT mixing studies with equal volumes 
of normal and patient plasma indicated a coagulation factor defi-
ciency. A severe FV deficiency (0.4%; reference range 70%- 120%) 
was established with a one- stage clotting assay, while the dosage of 
the other factors of the common coagulation pathway, factor II and 
factor X, showed normal results (respectively, 103% and 86%; refer-
ence ranges 70%- 120%). A mild factor VII deficiency (44%; reference 
range 70%- 130%) was also observed with a one- stage clotting assay. 
The FV deficiency was confirmed with a prothrombinase- based 
assay in 1:1000- diluted plasma.3 However, this condition was tran-
sient, as the FV level increased in the following days and was normal-
ized by day 32 after admission to the ICU. The course of the clotting 
times and the factor dosages are shown in Figure 1. At no point, the 
patient showed any signs of bleeding. She received several units of 
fresh frozen plasma and after 1 month she reached complete remis-
sion. Three months later, the patient relapsed and died as a result of 
the aggressive myeloma.
The cause of the transient FV deficiency in our patient could not 
be identified. No inhibitor could be found in the mixing studies, or 
in the Bethesda assay. This suggests another mechanism underlying 
the acquired FV deficiency. A possible explanation could be a bio-
synthesis problem as a result of liver failure. However, this would 
cause other coagulation factors to decline as well, according to their 
plasma half- lives. Another mechanism could be accelerated clear-
ance, possibly by a non- inactivating antibody that is not detected 
by our functional assays. The observation of the M- protein in multi-
ple myeloma acting as an autoantibody against specific coagulation 
factors has been described in individual cases for FII and FVIII, but 
to our knowledge not for FV.4 Besides the pathophysiology of the 
haematologic disorder itself, the treatment could also cause a factor 
deficiency. This has been reported for some therapies, for example 
6- Mercaptopurine in children with acute lymphoblastic leukaemia,5 
but not in the context of multiple myeloma. In contrast, the induction 
therapy for myeloma is known to induce a rise in prothrombotic co-
agulation factors, rather than a deficiency.6 Emori et al7 described a 
FV deficiency due to binding of the factor to amyloid fibrils. Binding 
to vascular or extravascular tissues could also be a possible explana-
tion.8 Interestingly, another myeloma patient with isolated acquired 
FV deficiency without inhibitor was recently reported.9
To evaluate the effects of the acquired FV deficiency on the pa-
tient’s overall coagulation function, we measured thrombin genera-
tion by calibrated automated thrombinography10 in plasma samples 
taken at day 8, 11, 18, 24 and 32 after admission of the patient to 
the ICU. Normal pooled plasma was measured in parallel as a refer-
ence. Coagulation was initiated either with a low tissue factor (TF) 
concentration (1.5 pmol/L) ± neutralizing antibodies against tissue 
factor pathway inhibitor α (TFPIα) (Figure 2A) or with a high TF 
concentration (10 pmol/L) ± activated protein C (APC) (Figure 2B). 
These different assay conditions were chosen to optimally monitor 
not only the procoagulant pathway, but also the main anticoagulant 
pathways (TFPIα and protein C systems).
At day 8, no thrombin generation was observed under any assay 
condition, in agreement with the patient’s severe FV deficiency 
(0.4%) at that point in time. As the patient’s FV level increased in 
the following days, thrombin generation became measurable (day 
11) and increased even far beyond the value of the normal pool (day 
18), but then decreased again (days 24 and 32), despite the steady 
increase in FV level, eventually normalizing at day 32. This pattern 
was observed under all assay conditions, but was most pronounced 
at low TF and at high TF in the presence of APC, where thrombin 
generation is most sensitive to the anticoagulant action of TFPIα.11 
Since FV acts as a carrier of TFPIα in the circulation, protecting it 
from truncation and/or clearance, plasma TFPIα levels are known to 
2  |     LETTER TO THE EDITOR
correlate with FV levels and to be markedly reduced in patients with 
congenital FV deficiency.3 This has also been described in one pa-
tient with an acquired FV deficiency.8 Therefore, we hypothesized 
that the decrease in thrombin generation observed at later time 
points might reflect an increase of the plasma TFPIα level in parallel 
to the FV level. This hypothesis was supported by the additional ob-
servation that the differences in thrombin generation at 1.5 pmol/L 
TF between days 18, 24 and 32 were largely (although not com-
pletely) abolished by the addition of anti- TFPI antibodies (Figure 2A).
The TFPIα levels in the patient’s plasma samples collected on dif-
ferent days were measured using an in- house ELISA.12 Interestingly, 
at days 8 and 11, when the patient was severely FV- deficient, her 
TFPIα level was also markedly reduced (±20%) and comparable to 
the TFPIα levels observed in patients with congenital FV deficiency.3 
However, her TFPIα level increased steadily in the next days, closely 
following the rise in FV level and reaching a normal value by day 
32. In fact, the plasma FV and TFPIα levels measured in the patient 
on different days showed a striking correlation (R² = 0.984), strongly 
F IGURE  1 Evolution of prothrombin 
time (PT), activated partial thromboplastin 
time (aPTT), factor V (FV) and tissue 
factor pathway inhibitor alpha (TFPIα) 
levels over a period of 40 d. On day 1, the 
patient was transferred to intensive care
F IGURE  2 Thrombin generation. A, At 1.5 pmol/L TF ± anti- TFPI antibodies. B, At 10 pmol/L TF ± APC at different concentrations. APC, 
activated protein C; aTFPI, anti- tissue factor pathway inhibitor antibodies; FV, factor V; TF, tissue factor
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suggesting that the rise in TFPIα level over time was driven by the 
progressive recovery of FV.
The co- variation between FV and TFPIα levels in the patient’s 
plasma and the different requirements of the pro- and anticoagu-
lant pathways may explain the outcome of the thrombin generation 
assays and provide some insights into the patient’s haemostatic 
balance at different time points. At days 8 and 11, the patient’s 
severe FV deficiency was the predominant defect, as reflected 
by the absent (day 8) or markedly delayed (day 11) thrombin gen-
eration. This hypocoagulable state may have been aggravated by 
the concomitant partial factor VII deficiency (as suggested by the 
prolonged lag time at day 11) and could not be effectively counter-
acted by the low TFPIα level. At this point, the patient might have 
been exposed to a bleeding risk, depending on her residual platelet 
FV, which we unfortunately did not have a chance to evaluate. At 
day 18, the patient’s FV had reached a sufficient level (31%) to 
guarantee maximal prothrombinase activity and adequate haemo-
stasis, while her TFPIα level (40%) was still suboptimal, resulting in 
a hypercoagulable state, pronounced APC resistance and possibly 
an increased risk of thrombosis, as demonstrated by the patient’s 
markedly elevated thrombin generation (especially at low TF and 
at high TF with APC) as compared to the normal pool. Reduced an-
ticoagulant activity of FV as cofactor of APC and TFPIα 1 may also 
have contributed to the hypercoagulable state at this time point. 
The imbalance between pro- and anticoagulant pathways was only 
resolved at day 32, when both FV and TFPIα had returned to their 
normal levels, yielding similar thrombin generation in the patient 
as in the normal pool under all experimental conditions.
Our results indicate that the findings of Duckers et al in congenital 
FV deficiency can be extended to acquired FV deficiency: within one 
and the same individual, the TFPIα concentration changes rapidly with 
the FV concentration, resulting in a hypocoagulable state at very low 
FV (and TFPIα) levels, but in a hypercoagulable state at intermediate FV 
(and TFPIα). In summary, we illustrated the interplay of FV and TFPI in 
a patient with acquired FV deficiency and we showed that the throm-
bin generation assay, performed under different conditions, can help to 
clarify the diverse and complicated mechanisms behind acquired factor 
deficiencies and their effects on the haemostatic balance.
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